Chemical formula: C₂₃H₃₂N₂O₅ Molecular mass: 416.511 g/mol PubChem compound: 5362129
Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09AA05 | Ramipril | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ALTACE Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RAMIPRIL Capsule, hard | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Ramipril is an active ingredient of these brands:
United States (US)Austria (AT)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
Germany (DE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Poland (PL)
Romania (RO)
South Africa (ZA)Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
